| 23.49 0.13 (0.56%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.94 | 1-year : | 39.27 |
| Resists | First : | 29.06 | Second : | 33.63 |
| Pivot price | 23.83  |
|||
| Supports | First : | 21.67 | Second : | 18.02 |
| MAs | MA(5) : | 23.18  |
MA(20) : | 25.08 |
| MA(100) : | 25.89 |
MA(250) : | 21.27 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 26.4 |
D(3) : | 21.1 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 33.63 | Low : | 10.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRPO ] has closed above bottom band by 40.7%. Bollinger Bands are 36.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 23.95 - 24.11 | 24.11 - 24.25 |
| Low: | 22.67 - 22.85 | 22.85 - 22.98 |
| Close: | 23.26 - 23.53 | 23.53 - 23.75 |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Tue, 26 May 2026
Precipio (PRPO) director-linked entity reports 900-share open-market sale - Stock Titan
Fri, 22 May 2026
Precipio Stock Slips Post Q1 Earnings Despite Revenue Growth - Yahoo Finance Singapore
Thu, 21 May 2026
Precipio (PRPO) director Sandberg reports 3,134-share net stock sale in Form 4 - Stock Titan
Thu, 14 May 2026
Precipio Announces Q1 2026 Financial Results - The Globe and Mail
Mon, 11 May 2026
B2i Digital Welcomes Precipio, Inc. as a New Featured Company - Yahoo Finance
Thu, 02 Apr 2026
Earnings call transcript: Precipio Inc. hits financial inflection in Q4 2025 - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.18 |
| Profit Margin | -1.6 % |
| Operating Margin | 8 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -2.8 % |
| Qtrly Rev. Growth | 22.8 % |
| Gross Profit (p.s.) | 5.98 |
| Sales Per Share | 13.43 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -52.21 |
| PEG Ratio | 0 |
| Price to Book value | 2.87 |
| Price to Sales | 1.74 |
| Price to Cash Flow | 61.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|